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Background: This multicenter phase II study investigated the efficacy and feasibility of preoperative induction
chemotherapy followed by chemoradiation and surgery in patients with esophageal carcinoma.
Patients and methods: Patients with locally advanced resectable squamous cell carcinoma or adenocarcinoma of
the esophagus received induction chemotherapy with cisplatin 75 mg/m2 and docetaxel (Taxotere) 75 mg/m2 on days
1 and 22, followed by radiotherapy of 45 Gy (25 · 1.8 Gy) and concurrent chemotherapy comprising cisplatin 25 mg/
m2 and docetaxel 20 mg/m2 weekly for 5 weeks, followed by surgery.
Results: Sixty-six patients were enrolled at eleven centers and 57 underwent surgery. R0 resection was achieved in
52 patients. Fifteen patients showed complete, 16 patients nearly complete and 26 patients poor pathological
remission. Median overall survival was 36.5 months and median event-free survival was 22.8 months. Squamous cell
carcinoma and good pathologically documented response were associated with longer survival. Eighty-two percent of
all included patients completed neoadjuvant therapy and survived for 30 days after surgery. Dysphagia and mucositis
grade 3/4 were infrequent (<9%) during chemoradiation. Five patients (9%) died due to surgical complications.
Conclusions: This neoadjuvant, taxane-containing regimen was efficacious and feasible in patients with locally
advanced esophageal cancer in a multicenter, community-based setting and represents a suitable backbone for
further investigation.
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introduction
Most patients with newly diagnosed carcinoma of the
esophagus present with locally advanced disease. Because of
high rates of locoregional and distant failure, there has been
much interest in combining local and systemic therapy.
Research conducted to date shows that adjuvant therapy does
not improve outcomes [1–4]. Thus, current research is focusing
on neoadjuvant strategies. In clinical practice, preoperative
chemoradiation is commonly used, although this strategy has
not shown a survival benefit over surgery alone in adequately
powered phase III trials [5–12], only in some meta-analyses
[13, 14]. The additional impact of surgery following
chemoradiation also remains unclear. Two randomized trials
showed an improvement in locoregional control following
surgery, but without any benefit in survival [15, 16].
The accepted standard approaches for locally advanced
esophageal cancer therefore include neoadjuvant chemotherapy
with or without radiation therapy and definitive
chemoradiation. Other variables which can influence treatment
outcome include different histologies implying different clinical
biology, the exact location of the tumor in the esophagus
which influences morbidity of surgery and several different
techniques of surgery and radiation therapy. Together with the
relative rarity of this disease and the necessity for intensive
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multidisciplinary teamwork in diagnostics and therapeutics,
large multicenter studies are difficult to carry out. Thus, many
pivotal phase III trials were carried out in single high-volume
institutions [5–7, 9, 10] and were often underpowered. However,
the results from studies carried out in highly specialized centers
often cannot be easily translated into clinical practice.
Based on these considerations, we initiated a nationwide,
multicenter phase II study in Switzerland investigating
neoadjuvant chemoradiation. In Switzerland, there are no high-
volume centers according to the international standards;
however, the essential preoperative multidisciplinary
evaluations are well established in both academic and
nonacademic centers. The neoadjuvant regimen under
investigation started with two cycles of induction
chemotherapy in order to prolong systemic treatment and to
reduce the severity of dysphagia before starting
chemoradiation. Fluorouracil, commonly used in other studies
in combination with cisplatin, was replaced by a taxane to
reduce mucositis during chemoradiation. Chemotherapy was
administered weekly during radiation therapy in an attempt to
enhance synergy with radiotherapy.
patients and methods
This was an open-label, multicenter phase II study. The protocol was
approved by the ethics committee of each participating institution, and all
patients gave written informed consent.
patient selection and evaluation
Previously untreated patients with locally advanced, histologically
confirmed squamous cell carcinoma or adenocarcinoma of the thoracic
esophagus including the gastroesophageal junction (Siewert type I), aged
18–70 years, with a World Health Organization performance status of zero
or one, adequate hematologic, renal and hepatic function were eligible. The
tumor had to be locally advanced but resectable (stage T3/N0, T1–3/N+ or
T4/Nx, if technically resectable with curative intent). Before registration,
a multidisciplinary team evaluated each patient to determine potential
resectability and operability. Patients were not eligible if metastases were
present including cervical or celiac lymph node involvement (M1a), if they
had concurrent cancer or uncontrolled significant comorbidity.
Pretreatment staging consisted of complete medical history, physical
examination, upper endoscopy with biopsy, helical computed tomography
(CT) scans of the chest and abdomen, endoscopic ultrasound (EUS) and
bronchoscopy if airway infiltration was suspected. A laparoscopy for
tumors of the lower third of the esophagus was optional. Positron emission
tomography (PET) or PET–CT staging was strongly recommended but not
mandatory. Obstructive tumors were considered locally advanced and
eligible for the trial even if a complete EUS was not feasible. Lymph nodes
were usually classified according to the EUS visual lymph node assessment
criteria of malignancy [17]. Any mismatch of different staging methods was
discussed by a multidisciplinary team including further investigations and
whether the patient would be eligible for the trial.
treatment plan
Preoperative treatment consisted of two cycles of induction chemotherapy
followed by chemoradiation. Induction chemotherapy consisted of cisplatin
75 mg/m2 and docetaxel (Taxotere, Aventis Pharma AG, Switzerland) 75
mg/m2 administered i.v. on days 1 and 22. Chemoradiation started after the
second induction chemotherapy cycle. Three-dimensional (3D) conformal
radiotherapy of 45 Gy (25 fractions of 1.8 Gy) was given over 5 weeks with
6–18 MV photons. The planning target volume included all known areas of
disease with a 5-cm cranial and caudal margin and a 2-cm lateral margin.
Spinal cord dose was limited to 36 Gy. All patients had 3D planning, the
correction of lung inhomogeneity was optional. Concomitant
chemotherapy consisted of i.v. cisplatin 25 mg/m2 and docetaxel 20 mg/m2
administered weekly for 5 weeks on an outpatient basis.
Surgery was scheduled 3–8 weeks after the completion of
chemoradiation. To proceed to surgery, patients were required to have no
evidence of newly detected stage M1 and/or inoperable T4 disease after
repeated chest and abdominal CT scanning and EUS. En bloc R0 resection
according to the International Union Against Cancer had to be carried out.
By definition, radical resection refers to the primary and to lymphatic
drainage areas as well. According to the localization of the tumor and the
preference of the surgeon, a thoraco-abdomino-cervical, thoraco-
abdomino-thoracal or abdomino-thoracal approach was taken. A complete
two-field lymphadenectomy was mandatory including resection of the
azygos vein. For adenocarcinoma of the gastroesophageal junction (Siewert
type I), a transhiatal partial esophagogastrectomy was allowed including
abdominal and partial para-esophageal lymphadenectomy. Barrett’s
mucosa and epithelial dysplastic mucosa had to be resected with the tumor.
Reconstruction could be done either with a stomach conduit or with
a transverse or ileocolon conduit according to the center’s preference.
dose modifications and follow-up
Toxicity was evaluated by National Cancer Institute—Common Toxicity
Criteria version 2.0. For the second induction chemotherapy cycle, cisplatin
and docetaxel were both postponed if the absolute neutrophil count (ANC)
was <1500/ll or if the platelet count was <100 000/ll. To start
chemoradiation, an ANC of ‡1000/ll and platelet counts of ‡75 000/ll
were necessary. During chemoradiation, docetaxel was omitted for 1 week if
the ANC was <1000/ll or platelet counts were <50 000/ll. Radiotherapy
and both drugs were stopped for 1 week if ANC was <500/ll and/or platelet
counts <25 000/ll after weekly reassessment. In case of febrile neutropenia
during chemoradiation, docetaxel was omitted whereas radiotherapy
and cisplatin were continued as judged by the local investigator.
In case of tumor- or treatment-induced dysphagia, tube feeding was
optional. Early insertion of a feeding tube was, however, recommended. In
cases of grade 3 therapy-induced esophagitis, radiotherapy was continued,
but the decision to continue chemotherapy depended upon the local
investigator. In cases of grade 4 esophagitis, both chemotherapy and
radiation were interrupted until toxicity resolved to grade 3.
Cisplatin was replaced by carboplatin if grade 3 peripheral neuropathy,
grade 2 hearing impairment or creatinine clearance <50 ml/min occurred.
For the second cycle of induction chemotherapy, carboplatin was given at
a dose of area under the concentration–time curve (AUC) 6 mgmin/ml,
and carboplatin AUC 2 mgmin/ml was given throughout chemoradiation.
In case of R1/2 resection, it was up to the local investigator to define
possible further local therapy.
Follow-up included CT scans and was carried out three monthly
following surgery or treatment failure during the first year, six monthly
during the next 3 years and yearly thereafter unless otherwise indicated
clinically. Endoscopic examination was carried out only if there were new
symptoms suggestive of local failure.
criteria for response and survival
Histopathological response was based on pathology findings after
esophagectomy. The specimens were evaluated according to the
standardized procedures by the local pathologists. The histopathological
response was classified according to the Mandard classification of ‘tumor
regression grade’ (TRG) [18]. TRG1 is defined as complete regression,
absence of histologically identifiable residual cancer and fibrosis extending
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through the different layers of the esophageal wall; TRG2 as presence of rare
residual cancer cells scattered through the fibrosis and TRG >2 as increased
number of residual cancer cells. All specimens were centrally reviewed at
the University of Basel by an experienced pathologist; in three cases, the
TRG by the local pathologist had to be revised.
Feasibility rate was defined as the proportion of patients who completed
the whole neoadjuvant therapeutic regimen and who survived for 30 days
after surgery. Event-free survival was defined as time from registration
to disease progression, relapse or death, whichever occurred first. The
pattern of failure was determined by the localization of tumor at the time
of relapse. Any relapse within the previous radiotherapy field was
considered a ‘local failure’.
statistics
We evaluated two primary end points, pathological complete remission rate
(pCR) and feasibility rate. The sample size was calculated to have a power
of 90% and a significance level of 5% based on Bryant and Day’s design
[19], which is a modification of Simon’s two-stage design for two primary
end points [20].
A pCR rate (i.e. TRG1) of 30% was considered promising for further study,
and a rate of 15% was considered insufficient. A feasibility rate of 70% was
considered acceptable while a rate of 50% was considered unacceptable.
The trial was to be stopped after a first stage of 22 patients if only three
patients or fewer had a TRG of 1 or if only 11 patients had successfully
completed treatment. Otherwise, the trial plan was to accrue 44 more
patients in a second stage. Hence, the sample size for this study was 66.
Survival analysis was done on an intention-to-treat basis.
Serious adverse events and response rates were continuously monitored
by the Schweizerische Arbeitsgemeinschaft fu¨r Klinische Krebsforschung
(SAKK) Coordinating Center. The interim results were presented to the
SAKK Executive Committee before a definitive decision about continuation
or early stopping was made.
results
patient and tumor characteristics
From July 2003 to June 2006, 66 patients were enrolled at 11
centers. Seven of the centers were non-university hospitals and
contributed 70% of the patients. Patient and tumor
characteristics are listed in Table 1. Most patients were male
and had stage T3, N0–1 disease. Four patients did not undergo
endosonography because of obstructing esophageal lesions;
their stage was therefore at least T3 by definition. A PET scan or
an integrated PET–CT scan was carried out at baseline in 56
patients; 8 of the 10 remaining patients were treated at centers
where PET was not yet available, one patient refused the PET
scan and one PET scan was carried out after starting therapy.
treatment outcomes
An accrual and treatment summary is depicted in Figure 1.
Four patients progressed during neoadjuvant therapy; three of
whom had newly diagnosed distant disease.
Four patients did not undergo surgery, one due to severe
lung embolism and in three cases because the tumor was not
expected to be R0 resectable even though the tumor had not
progressed under neoadjuvant therapy. In addition, one patient
was operated after 3-month delay after reversing his initial
decision to refuse surgery. Eighty-two percent of all patients
fulfilled in an intention-to-treat analysis the primary endpoint
for feasibility according to the definition in the protocol
(completing neoadjuvant therapy and surviving for 30 days
after surgery).
The surgical outcome is listed in Table 2. Three patients with
squamous cell carcinoma in the distal part of the esophagus
received a transhiatal resection only, which formally was
a protocol violation. According to the protocol, surgical
mortality was defined as death occurring within 30 days
postoperatively and affected only one patient (1.8%). However,
another four patients died after 30 days postoperatively due to
surgical complications (Table 2).
Among the 57 patients who underwent surgery, 53 (93%)
had disease-free margins. In an intention-to-treat analysis, the
second primary end point pCR (TRG1) was reached by 23% of
all included patients, an additional 24% showed a near
complete remission (TRG2). It is worth to mention that 38% of
all patients with squamous cell cancer achieved pCR compared
with only 16% with adenocarcinoma.
At a median follow-up of 29 months (range 5–53 months),
39 patients were still alive. The Kaplan–Meier estimates of
overall survival rate at 2 and 3 years was 66% and 53%,
respectively. The median overall survival and median event-free
Table 1. Patient and Tumor Characteristics
Adenocarcinoma Squamous cell
carcinoma
Total
n % n % n %
No. of patients 36 100 30 100 66 100
Age, years
Median 61 59 61
Range 35–70 41–70 35–70
Sex
Male 31 86 25 83 56 85
Female 5 14 5 17 10 15
Clinical stage
T1N1 1 3 0 0 1 2
T2N1 6 17 5 17 11 17
T3N0 5 14 4 13 9 14
T3N1 22 61 18 60 40 61
T3Nx 2 6 2 7 4 6
T4N1 0 0 1 3 1 2
WHO grade
1 2 6 3 10 5 8
2 16 44 17 57 33 50
3 16 44 10 33 26 39
Not determined 2 6 0 0 2 3
Barrrett’s
metaplasia
12 33 1 3 13 20
ECOG performance
status
0 24 67 21 70 45 68
1 12 33 9 30 21 32
Dysphagia gradea
0/1 27 75 18 60 45 68
2 8 22 11 37 19 29
3 0 0 1 3 1 2
4 1 3 0 0 1 2
aAccording to National Cancer Institute—Common Toxicity Criteria
version 2.0.
WHO, World Health Organization; ECOG, Eastern Cooperative Oncology
Group.
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survival (progression or death) of all patients was 36.5 and 22.8
months, respectively (Figure 2). The event-free survival for
patients with adenocarcinoma was 22.3 months, for patients with
squamous cell carcinoma 27.9 months and for patients with a
good response (TRG1 + 2) was 27.9 months compared with 17.0
months for poor responders (TRG > 2) (Figure 2).
Table 3 gives an overview of the sites of first failure and
causes of death. Two patients died of unknown causes at home,
one without and one with previously diagnosed relapse. Of
the surgery-related deaths, only one patient had a known
persisting tumor. Among the 27 patients who have died to date,
tumor relapse was diagnosed in 21.
toxicity and treatment compliance
The toxicity profile of induction chemotherapy and
chemoradiation is listed in Table 4. The hematologic and
non-hematologic toxicity of induction chemotherapy was as
expected and manageable. In seven patients, the dose of
docetaxel, and in four patients the doses of both docetaxel
and cisplatin, had to be reduced by 25% for the second cycle,
mainly because of gastrointestinal toxicity.
Of 65 patients undergoing chemoradiation, 54 (83%)
received full-dose radiation therapy together with all weekly
doses of both drugs. Nine of the remaining 11 patients received
full-dose radiation therapy but missed one weekly dose of
chemotherapy. Of the two remaining patients, one patient
stopped chemoradiation after 27 Gy because of unacceptable
pain due to dysphagia. In the other patient, the first four weekly
doses of chemotherapy were withheld because of covered
esophageal perforation after induction chemotherapy. During
chemoradiation, cisplatin had to be replaced by carboplatin in
six patients due to impaired creatinine clearance and in one
case because of grade 2 hearing loss. In four patients, feeding
tubes were inserted before treatment; however, two of them
were not needed because of rapid improvement of dysphagia
during induction chemotherapy. Only two feeding tubes were
inserted during neoadjuvant therapy because of poor
nutritional status.
discussion
The objectives of this trial were to evaluate efficacy, toxicity,
pattern of failure and feasibility of a taxane-containing,
Figure 1. Accrual and treatment summary.
Table 2. Surgical outcomes: histopathological response, morbidity and
mortality
Adenocarcinoma Squamous cell
carcinoma
Total
n n n
Eligible patients 36 30 66
No surgery performed 5 4 9
n % n % n %
Total surgery 31 100 26 100 57 100
Type of surgery
Abdomino-thoracal resection 13 42 23 88 36 63
Transhiatal resection 18 58 3 12 21 37
Resections achieved
R0 29 94 24 92 53 93
R1 1 3 2 8 3 5
R2 1 3 0 0 1 2
Histopathological response rate
TRG 1 (pCR) 5 16 10 38 15 26
TRG 2 8 26 8 31 16 28
TRG 3–5 18 58 8 31 26 46
Deaths due to
Complications of surgery 1 3 4 15 5 9
ARDS and multiorgan
failure
0 0 3 12 3 5
Anastomotic leakage and
fatal bleeding
0 0 1 4 1 2
Anastomotic leakage/sepsis 1 3 0 0 1 2
Nonfatal complications
Pneumonia 3 10 5 19 8 14
Other infection 5 16 2 8 7 12
Intra-abdominal abscess or
peritonitis
1 3 0 0 1 2
Anastomotic leakage 1 3 4 15 5 9
Chylous fistula 4 13 2 8 6 11
Vocal cord palsy 2 6 0 0 2 4
pCR, pathological complete remission rate; TRG, tumor regression grade;
ARDS, acute respiratory distress syndrome.
Annals of Oncology original article
Volume 20 | No. 9 | September 2009 doi:10.1093/annonc/mdp045 | 1525
multimodal treatment strategy for patients with locally
advanced esophageal carcinoma in a multicenter setting. Nearly
all centers treating patients with esophageal cancer in
Switzerland, a country of 7 million inhabitants, participated in
this trial. Over 80% of patients included in the study had T3
tumors, most of them with node-positive disease, representing
a poor-prognosis group of patients. However, patients with
more extensive disease were excluded with good reliability
because disease stage was accurately determined using CT scan,
endosonography and, in most cases, a PET scan. The feasibility
of this neoadjuvant regimen was very encouraging regarding
the compliance with the study protocol in a multicenter setting
and the adverse events. Sixty-three out of 65 nonprogressing
patients received two cycles of induction chemotherapy,
Figure 2. Kaplan–Meier plots according to intention-to-treat analysis showing (A) overall survival as time from registration to death; (B) event-free survival
as time from registration to disease progression, relapse or death; (C) survival among patients according to histology type and (D) survival among patients
according to histopathological response.
Table 3. Sites of first failure, survival status and causes of death
Adenocarcinoma (n = 36) Squamous cell carcinoma (n = 30) Total (n = 66)
n % n % n %
Alive and without residual or recurrent disease 12 33 15 50 27 41
Death without known recurrent disease 2 6 4 13 6 9
Relapse 22 61 11 37 33 50
Residual disease (R1/R2) 2 6 2 7 4 6
Locoregional recurrence 7 19 3 10 10 15
Distant metastases 12 33 2 7 14 21
Local recurrence and distant metastases 1 3 4 13 5 8
Deaths 17 47 10 33 27 41
Cancer related 13 36 6 20 19 29
Chemoradiation related 0 0 0 0 0 0
Surgery related 1 3 4 13 5 8
Death from other cause without tumor 1 3 0 0 1 2
Death from unknown cause 2 6 0 0 2 3
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full-dose radiation therapy and at least four of five weekly doses
of concomitant chemotherapy. Of note, severe chemoradiation-
related mucositis and dysphagia (grade 3 and 4) occurred in
<10% of patients. The two cycles of induction chemotherapy
contributed to improved swallowing and nutritional status in
patients originally presenting with relevant tumor-related
dysphagia. The low incidence of inserted feeding tubes during
neoadjuvant therapy supports this observation. We speculate
that the replacement of fluorouracil, frequently used in this
situation, with docetaxel may have contributed to the decreased
severity of mucositis as well.
Eighty-six percent of all included patients underwent surgery
following induction chemotherapy and chemoradiation
therapy. Ninety-three percent of all operated patients
underwent an R0 resection, an important factor for long-term
survival. The per-protocol definition of surgical mortality
ending after 30 days, as in most other comparable trials, was
low. However, the effective surgery-related mortality after
neoadjuvant chemoradiation was 8.8% after taking into
account later deaths that were clearly surgery related. This is
similar to other trials of preoperative chemoradiation [2, 5, 15,
21], even including those reporting single-center experience [5,
21].
Postoperative complications included three cases of acute
respiratory distress syndrome and eight cases of severe
pneumonia, possibly related to the intensive type of
chemoradiation. From our point of view, the centralization of
care to experienced centers for this type of surgery remains
crucial to reduce the complication rate further. Overall, the
feasibility rate of this regimen was 82% on an intention-to-treat
analysis, well within the feasibility target of this trial.
One primary efficacy end point of this trial was pCR rate.
Ajani et al. [22] reported in 2007 that the pathological stage of
the resected specimen after neoadjuvant chemoradiation is
a determinant of patient survival rather than baseline clinical
stage. We decided to classify the tumor regression grade
according to Mandard et al. [18]. The high reliability of the
TRG determination in our trial was confirmed by central
review similar to another group [23]. With a pCR rate of 23%
of all included patients we failed to reach the prospectively
defined goal of this trial regarding efficacy. During the conduct
of our study, the Siewert group validated the Mandard
pathologically documented response classification and showed
no significant survival difference between TRG1 (pCR) and
TRG2 (1%–10% residual tumor cells) [24]. When using the
Mandard histopathological classification, the line between no
residual cancer cells (TRG1) and very rare residual cancer cells
(TRG2) is often arbitrary, and pathologists usually classify
response as TRG2 if they are uncertain if scattered tumor cells
are alive or dead. Therefore, our rather low pCR rate is not easy
to compare with those derived from studies using other
classification systems. The potential clinical benefit may be
better appreciated taking as well into account the rate of TRG 2.
Including this aspect, the neoadjuvant regimen under study
was efficacious, with 47% of patients reaching a good
histopathological response (TRG 1 + 2) in an intention-to-treat
analysis. This result correlated with excellent survival outcomes
for this poor-prognosis group of patients, with a median overall
survival of 36.5 months and a median event-free survival of
23 months for all patients. Most published phase II trials and
some phase III trials are single-center studies, and therefore it
is difficult to compare them with our trial. However, the
outcomes of this multicenter trial compare favorably with
reported results from other multicenter trials [8, 10, 11, 25],
although this trial was conducted in a community-based setting
without high-volume centers. A reason for the favorable
outcome could be the inclusion of a very homogeneous group
of accurately staged patients. Other studies found a correlation
Table 4. Adverse events of the preoperative regimen
Adverse events Induction chemotherapy (n = 66) Neoadjuvant chemoradiotherapy (n = 65)
All grades Grade 3/4 All grades Grade 3/4
n % n % n % n %
Anemia 59 89 2 3 64 98 1 2
Thrombocytopenia 26 39 0 0 41 63 2 3
Neutropenia 44 67 34 52 9 14 0 0
Dysphagia 58 88 3 5 58 89 5 8
Mucositis 8 12 3 5 7 11 1 2
Diarrhea 25 38 7 11 5 8 0 0
Nausea 33 50 1 2 36 55 0 0
Vomiting 13 20 2 3 20 31 0 0
Febrile neutropenia 11 17 11 17 0 0.0 0 0
Neuromotor 1 2 0 0 2 3 0 0
Neurosensory 0 0 0 0 0 0 0 0
Hearing impairment 7 11 0 0 3 5 0 0
Alopecia 40 61 0 0 55 85 0 0
Asthenia 35 53 4 6 42 65 4 6
Dermatology 0 0 0 0 15 23 0 0
Other toxicity 58 88 6a 11 55 85 8b 12
aDyspnea (n = 1), syncope (n = 1), colitis (n = 1), loss of appetite (n = 1), infection (n = 1) and dehydration (n = 1).
bDyspnea (n = 1), pneumonia (n = 1), syncope (n = 1), dehydration (n = 2), hypokalemia (n = 1), arrhythmia (n = 1) and anorexia (n = 1).
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between histopathological response and survival [9, 24, 26],
a finding that is supported by our results. However, in our
study, patients with squamous cell cancer had a better response
rate and survival than patients with adenocarcinoma, although
not statistically significant. One could think that the adding of
a taxane is more efficient for patients with squamous cell
carcinoma than for patient with adenocarcinoma.
The prognosis of locally advanced esophageal cancer remains
poor, and further investigations of neoadjuvant therapy should
aim to improve efficacy while maintaining feasibility and
acceptable toxicity. From our point of view, surgery so far
remains an essential modality for achieving locoregional
control of this disease as shown in several publications [15, 16,
27]. However, both the achievement of symptom relief with
neoadjuvant therapy or, conversely, deterioration of overall
condition may prevent patients from undergoing planned
surgery in randomized trials. This may weaken the surgical arm
and also be responsible for the lack of documented significant
benefit of neoadjuvant strategies. This neoadjuvant regimen
represents a suitable backbone for further investigation given its
high efficacy with regard to R0 resection rate, response rate and
event-free survival as well as high patient compliance and
feasibility in a multicenter, community-based setting.
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